EBS | Emergent BioSolutions Inc. Stock Overview

(Stock Exchange: NYSE)

Day's Range	6.75 - 7.37
52 Week Range	1.4200 - 15.10
Beta	2.45
Implied Volatility	123.05%
IV Rank	27.78%
Day's Volume	1,599,970
Average Volume	3,185,203
Shares Outstanding	52,906,600
Market Cap	365,055,540
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2006-11-15

Valuation
Profitability
Growth
Health
P/E Ratio	-0.61
Forward P/E Ratio	-32.98
EPS	-11.22
1YR Price Target	37.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	2016-08-01
Dividend PayDate	N/A
Employees	1,600
Country	USA
Website	EBS

Emergent BioSolutions offers public health products to government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccine, device, and therapeutic products.

EBS's peers: BHC, DVAX, ZTS, PETQ, NBIX, AKAN, LFCR, PBH, ITCI, IZQVF, ALKS, CPIX, DCPH, COLL, DRRX, TAK, VTRS, HLN

*Chart delayed

Analyzing fundamentals for EBS we got that it has weak fundamentals where Valuation is considered to be fairly valued, Profitability is unacceptably poor, Growth is very bad and Health is frighteningly weak. For more detailed analysis please see EBS Fundamentals page.

Watching at EBS technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on EBS Technicals page.